| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.6 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | serdemetan | FIMM | pan-cancer | AAC | -0.078 | 0.6 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | phenformin | GDSC1000 | pan-cancer | AAC | 0.015 | 0.6 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.6 |